Vaccines and Global Health: The Week in Review
04 March 2023 :: Issue 693
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf:  If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
Milestones, Perspectives

“Pandemic Treaty’

Countries begin negotiations on global agreement to protect world from future pandemic emergencies
3 March 2023
WHO News release
Countries of the World Health Organization have begun negotiations on a global accord on pandemic prevention, preparedness and response, using the “zero draft” as a basis for negotiating an agreement to protect nations and communities from future pandemic emergencies.

Ending Friday, discussions on the draft pandemic accord took place during the weeklong fourth meeting of the Intergovernmental Negotiating Body (INB), which includes WHO’s 194 countries. Negotiations on the draft will continue over the next year according to a timetable laid out by the World Health Assembly.

Mr Roland Driece, Co-Chair of the INB Bureau, from the Netherlands, said: “The start of discussions of concrete language for the WHO pandemic accord sends a clear signal that countries of the world want to work together for a safer, healthier future where we are better prepared for, and able to prevent future pandemic threats, and respond to them effectively and equitably.”

Fellow INB Bureau Co-Chair, Ms Precious Matsoso of South Africa, said: “The efforts this week, by countries from around the world, was a critical step in ensuring we do not repeat the mistakes of the COVID-19 pandemic response, including in sharing life-saving vaccines, provision of information and development of local capacities.” ...

WHO Member States will continue negotiations of the zero draft of the pandemic accord at the INB’s next meeting, to be held over 3-6 April, with a view to collecting all inputs necessary to develop the first draft.

According to the process agreed by governments at a special session of the World Health Assembly in late 2021, negotiations on the draft pandemic accord will aim to produce a final draft for consideration by the 77th World Health Assembly in 2024.

...In parallel with the pandemic accord negotiations, governments are also discussing more than 300 amendments to the International Health Regulations (2005) in an effort to make the world safer from communicable diseases and ensuring greater equity in the global response to public health emergencies.

Governments have been working to ensure consistency and alignment across the INB and IHR processes. The proposed IHR amendments will also be presented to the World Health Assembly in 2024, and would together, with a future pandemic accord, provide a comprehensive, complementary, and synergistic set of global health agreements.
Summary
Background
Understanding the level and characteristics of protection from past SARS-CoV-2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe disease is essential for predicting future potential disease burden, for designing policies that restrict travel or access to venues where there is a high risk of transmission, and for informing choices about when to receive vaccine doses. We aimed to systematically synthesise studies to estimate protection from past infection by variant, and where data allow, by time since infection.

Methods
In this systematic review and meta-analysis, we identified, reviewed, and extracted from the scientific literature retrospective and prospective cohort studies and test-negative case-control studies published from inception up to Sept 31, 2022, that estimated the reduction in risk of COVID-19 among individuals with a past SARS-CoV-2 infection in comparison to those without a previous infection. We meta-analysed the effectiveness of past infection by outcome (infection, symptomatic disease, and severe disease), variant, and time since infection. We ran a Bayesian meta-regression to estimate the pooled estimates of protection. Risk-of-bias assessment was evaluated using the National Institutes of Health quality-assessment tools. The systematic review was PRISMA compliant and was registered with PROSPERO (number CRD42022303850).

Findings
We identified a total of 65 studies from 19 different countries. Our meta-analyses showed that protection from past infection and any symptomatic disease was high for ancestral, alpha, beta, and delta variants, but was substantially lower for the omicron BA.1 variant. Pooled effectiveness against re-infection by the omicron BA.1 variant was 45·3% (95% uncertainty interval [UI] 17·3–76·1) and 44·0% (26·5–65·0) against omicron BA.1 symptomatic disease. Mean pooled effectiveness was greater than 78% against severe disease (hospitalisation and death) for all variants, including omicron BA.1.

Protection from re-infection from ancestral, alpha, and delta variants declined over time but remained at 78·6% (49·8–93·6) at 40 weeks. Protection against re-infection by the omicron BA.1 variant declined more rapidly and was estimated at 36·1% (24·4–51·3) at 40 weeks. On the other hand, protection against severe disease remained high for all variants, with 90·2% (69·7–97·5) for ancestral, alpha, and delta variants, and 88·9% (84·7–90·9) for omicron BA.1 at 40 weeks.

Interpretation
Protection from past infection against re-infection from pre-omicron variants was very high and remained high even after 40 weeks. Protection was substantially lower for the omicron BA.1 variant.
and declined more rapidly over time than protection against previous variants. Protection from severe
disease was high for all variants. The immunity conferred by past infection should be weighed
alongside protection from vaccination when assessing future disease burden from COVID-19, providing
guidance on when individuals should be vaccinated, and designing policies that mandate vaccination
for workers or restrict access, on the basis of immune status, to settings where the risk of transmission
is high, such as travel and high-occupancy indoor settings.

Funding

Featured Journal Content

Science Translational Medicine
Volume 15| Issue 685| 1 Mar 2023
https://www.science.org/toc/stm/current

Viewpoint
Vaccines for a sustainable planet
BY Simone Pecetta, Arindam Nandi, Charlie Weller, Vanessa Harris, Helen Fletcher, Francesco
Berlinda, Scorza Mariagrazia Pizza, David Salisbury, Richard Moxon, Steve Black[...]
Rino Rappuoli
01 Mar 2023

Free

Abstract
The health of the planet is one objective of the United Nations’ Sustainable Development Goals.
Vaccines can affect not only human health but also planet health by reducing poverty, preserving
microbial diversity, reducing antimicrobial resistance, and preventing an increase in pandemics that is
fueled partly by climate change.

...CONCLUSIONS
We have made the case that, in addition to their contribution to the health and economic
well-being of people, vaccines also promote planetary health and sustainability. This is
important because the health and well-being of the global population—a main goal of vaccination—
cannot be achieved if the health of planet Earth continues to deteriorate. The 17 SDGs, the 2015–2030
global initiative of the UN to protect the planet’s health, will have a midterm review this year.
Implementation of the SDG agenda has been delayed considerably by the socioeconomic disruption
caused by the COVID-19 pandemic.

However, the COVID-19 pandemic has clearly demonstrated the major contribution of
vaccines to regaining the health and freedom of the world’s population. Vaccines, a
powerful tool to reduce poverty and improve human well-being, can directly affect many
of the SDGs and will help to accelerate progress toward achieving these crucial goals
(Fig. 1B).
We suggest incorporating vaccines into the revised SDGs, with the following recommendations. First, massively increase the public sector budget for vaccine research and development (R&D), to the order of US$30 billion per year for the next 10 years, to
create better vaccines against known diseases and to prepare prototype vaccines for rapid response to outbreaks. These vaccines will protect the world in the realms of poverty, overpopulation, and carbon footprint. Together with vaccine R&D investment, additional investments are needed to expand the global public health infrastructure. Expanding health capacity in all regions of the world may require an additional US$70 billion per year for the next 10 years to improve diagnostics, capacity for routine immunization, clinical trials, and emergency vaccination. During the early stages of the COVID-19 pandemic, when the global economy loss was about US$500 billion per month, the Operation Warp Speed investment of US$12.4 billion was acceptable. Although our investment proposals may seem massive, the total investment proposed is only 0.001% of global gross domestic product and less than 14% of the annual defense budget of the United States. To avoid cycles of inattention to global health threats followed by panic and corrective actions, we should not wait for the next pandemic. To make this happen, changes in financial arrangements and models of public-private cooperation that leverage the COVID-19 pandemic experience should occur (41). Our proposal aligns closely with the so-called “trillion-dollar vaccine gap” recently described, which advocated for a 10-fold increase of investment in vaccine development and distribution to achieve global equitable vaccine access and pandemic preparedness, and with the view that investment in health drives extraordinary returns, but being a public good, it requires public investment (42).

Second, to prevent the emergence of new pandemics, there needs to be funding for developing prototype vaccines against potential pandemic viruses and new vaccine platforms, as well as equitable R&D capacity, vaccine manufacturing, and vaccine distribution. This includes building R&D and manufacturing capacity in all regions of the world. Third, preventing AMR and preserving functional microbial diversity in humans, animals, and the environment will necessitate prioritizing and funding vaccines that target AMR-bearing pathogens and reducing antimicrobial usage in human, animal, and agricultural sectors.

In line with the necessity to determine how to measure the contribution of improved vaccine availability to sustainable development, we propose a task force of experts to estimate the actual and prospective benefits of vaccines and vaccination with respect to the achievement of SDGs. The outcome could inform ongoing SDG reviews and provide rigorous evidence that vaccines can and do play a major role in advancing the agenda of the UN SDGs, improving planetary health, and benefiting the whole of humanity.

::::::
::::::

Boosting investment in health systems will be essential to deal with future shocks, says OECD
OECD 23/02/2023
Governments should urgently adapt their health systems to better respond to future shocks, given the huge impact of the COVID-19 pandemic on people and the global economy. Major investment is needed in the health workforce, alongside increased spending on prevention and digital infrastructure, according to a new OECD report.

Ready for the Next Crisis? Investing in Health System Resilience says that even the most advanced health systems in the world were not resilient to the COVID-19 pandemic. In 2020, life expectancy fell in 75% of OECD countries. Around 34% of all cumulative COVID-19 deaths were among residents in
long-term care facilities by April 2022. The report emphasises three major vulnerabilities: health systems were underprepared and understaffed and faced underinvestment.

On average, 35% of the population of OECD countries had a longstanding illness or health problem in 2019. A high prevalence of chronic disease makes populations less resilient and increased COVID-19 mortality. Yet OECD health systems spent less than 3% of total health expenditure on prevention. People are key to making systems resilient, says the report. Not having sufficient healthcare workers affected the quality of care during the first year of the pandemic more than, for instance, the number of hospital beds. More workers in health and social care were associated with lower mortality rates.

“There are significant social and economic dividends from health system resilience. Countries need to improve the preparedness of their health systems for the next crisis in order to improve resilience to reduce the impact of shocks and accelerate recovery,” OECD Secretary-General Mathias Cormann said.

“Promoting population health, health and social care workforce retention, data collection and use, international cooperation, supply chain resilience, and governance and trust can help to improve access to health services, health and well-being, and full participation in society.”

The legacy of the pandemic could endure for decades. Healthcare worker well-being suffered and has not recovered. A substantial backlog in care remains. For example, 11 million fewer diagnostic and elective surgical procedures were performed in 2020 compared with 2019, across 31 OECD countries. This is compounded by new challenges, including treating “long COVID”, and meeting the substantial increase in mental health care needs, especially in young people. Workforce shortages persist and limit the resolution of this backlog.

Boosting the resilience of health systems requires smart investments, better co-ordination (including to build more resilient medical supply chains) and improved global health co-operation. This report recommends an annual targeted investment of 1.4% of GDP across OECD countries relative to expenditure in 2019. Bolstering the health and long-term care workforce on the front-line accounts for around half of this recommended investment. This would mean over three million additional workers across OECD countries.

The report also proposes investments in health data infrastructure, including to promote quality, real-time information in response to shocks; in preventive and primary care to protect populations; in the development of health technologies needed to address future threats, and in capacity to ensure these technologies can be deployed effectively and equitably.


**PHEIC**

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates

Last update: 17 Feb 2023
Weekly epidemiological update on COVID-19 - 1 March 2023

Overview
Globally, over 4.8 million new cases and over 39 000 deaths were reported in the last 28 days (30 January to 26 February 2023), a decrease of 76% and 66%, respectively, compared to the previous 28 days. As of 26 February 2023, over 758 million confirmed cases and over 6.8 million deaths have been reported globally.

Figure 1. COVID-19 cases reported by WHO Region, and global deaths by 28-day intervals, as of 26 February 2023**
Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 04 Mar 2023]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability
Duke – Launch and Scale Speedometer
**The Race for Global COVID-19 Vaccine Equity**
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/
COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

Feb 25, 2023 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 125M total confirmed cases; 2.3M total confirmed deaths

Global vaccines administered: 13.3B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 390M
Other Delivered (Number of Doses): 430M
Total Delivered (Number of Doses): 830M
Total Administered (Number of Doses): 590M

U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
No new digest content identified.

FDA
Press Announcements
FDA Roundup: March 3, 2023

...On Wednesday, the FDA issued a discussion paper on artificial intelligence in drug manufacturing to help proactively prepare for the implementation of AI in drug manufacturing and its enabling digital infrastructure. The agency is asking interested stakeholders to provide input on certain areas of consideration identified in the discussion paper. Public feedback will help inform the FDA’s evaluation of
our existing regulatory framework in the context of AI’s in drug manufacturing to ensure production of quality drugs for U.S. patients.

**FDA VRBPAC**

**Vaccines and Related Biological Products Advisory Committee March 7, 2023 Meeting Announcement - 03/07/2023**

Meeting Information
Event Materials

::::::::::

Europe: **COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**European Medicines Agency [EMA]**

*News & Press Releases*
*No new digest content identified.*

::::::::::

**European Centre for Disease Prevention and Control**

https://www.ecdc.europa.eu/en
*News/Updates/Reports [Selected]*

**ECDC de-escalates BA.2, BA.4 and BA.5 from its list of variants of concern**

News story - 3 Mar 2023

**Weekly COVID-19 country overview**

Epidemiological update - 3 Mar 2023

**Joint ECDC-WHO/Europe mpox (monkeypox) surveillance bulletin**

Epidemiological update - 1 Mar 2023

**Cluster of avian influenza in Cambodia**

News story - 1 Mar 2023

**Mpox (formerly named monkeypox) situation update**

Epidemiological update - 28 Feb 2023

::::::::::

**Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**

https://africacdc.org/covid-19-vaccination/
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V — "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
China

The Guardian
WHO calls on US to share information on Covid-19 origins after China lab claims
World Health Organization’s director general says the politicisation of research into Covid’s origins was making the scientific work harder
Agence France-Presse
Fri 3 Mar 2023
The World Health Organization has urged all countries to reveal what they know about the origins of Covid-19, after claims from several US government agencies that a Chinese lab leak was behind the disease were furiously denied by Beijing.
“If any country has information about the origins of the pandemic, it’s essential for that information to be shared with WHO and the international scientific community,” the WHO director general, Tedros Adhanom Ghebreyesus, said on Friday...

Washington Post
Opinion
China should answer how covid-19 began. Propaganda is no substitute.
By the Editorial Board
March 2, 2023

PHEIC
Mpox
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

Last Situation Report:
Multi-country outbreak of mpox, External Situation report # 17 - 2 March 2023
Overview
This is the 17th situation report for the multi-country outbreak of mpox, which provides details on the latest epidemiology of mpox, vaccines for mpox and an update from the WHO South-East Asia Region and Central America and the Carribean.

Highlights
- Since the last situation report published on 16 February 2023, 313 new mpox cases (0.4% increase in total cases) and eight new related deaths have been reported to WHO.
- The latest epidemiological data suggests the outbreak is heading towards an end in the European Region, and slowing down in the Region of the Americas where human-to-human transmission occurs.
- In the African region where the infection also occurs through contact with infected animals, the epidemic curve shows more sustained transmission, reflecting mixed patterns of human-to-human transmission through direct or sexual contact as well as outbreaks due to zoonotic spillover events.
- In November 2022, a vaccine called OrthopoxVac was licensed in the Russian Federation for immunization against smallpox, mpox and other orthopoxviruses according to the rules for registration of medicines of the Eurasian Economic Union.

---

**PHEIC**

**Polio**

**Polio this week as of 01 March 2023 - GPEI**

*Headlines*
:: The European Polio Conference will be held on 25-27 May in Nancy, France. Organized by Polio-France in cooperation with the European Polio Union (EPU), the conference is aimed at people with polio and post-polio syndrome from all over the world, as well as health professionals concerned with the management of polio and post-polio syndrome. Registration details and further information available [here](#).
:: The United Nations Foundation has released a new report: “Leveraging CSO Contributions to Advance Polio Transition and Integration Efforts in the African Region”. The report highlights the critical role of civil society in advancing polio transition and integration efforts in Africa and outlines key recommendations for how to expand and enhance the contributions of civil society to this crucial work.

*Summary of new polioviruses this week:*
- Algeria: two cVDPV2 positive environmental samples
- Benin: one cVDPV2 case
- Botswana: two cVDPV2 positive environmental samples
- Cameroon: one cVDPV2 case
- Congo: one cVDPV1 case
- DRC: 13 cVDPV1 cases, eight cVDPV2 cases and one cVDPV2 positive environmental sample
- Malawi: one cVDPV2 positive environmental sample
- Mali: one cVDPV2 case
- Somalia: one cVDPV2 case and one positive environmental sample
- Yemen: one cVDPV2 case

---

**UN OCHA – Current Emergencies**

*Current Corporate Emergencies*

**Afghanistan**
Editor’s Note:
We observe that OCHA has removed Afghanistan from its listing of “Current Emergencies.” We did not identify any explanation for its removal.

**Northern Ethiopia**
No new digest content identified.

**Somalia**
No new digest content identified.

**Türkiye/Syria Earthquakes**
No new digest content identified.

**Ukraine**
Last Updated: 10 Feb 2023

:::::::

**WHO & Regional Offices** [to 04 Mar 2023]
https://www.who.int/news
Selected News/Announcements/Statements
3 March 2023
News release
**Countries begin negotiations on global agreement to protect world from future pandemic emergencies**

3 March 2023
Departmental news
**New compendium showcases positive examples in refugee and migrant health**

1 March 2023
Departmental news
**Countries urged to safeguard the health of refugees and migrants**

1 March 2023
News release
**Visit of WHO Director-General to north-west Syria**

1 March 2023
Departmental news
**Registration Open: Please apply to join the UN Multi-stakeholder Hearing on TB on 8-9 May**

28 February 2023
Departmental news
**The Montreux Charter on Patient Safety galvanizes action to address avoidable harm in health care**
27 February 2023
Departmental news

**WHO rolls out new holistic way to measure early childhood development**

::::::

**WHO Regional Offices**
Selected Press Releases, Announcements

**WHO African Region**
:: 02 March 2023  **Floods raise cholera risk even as cases decline in Africa**
Brazzaville – As weekly cholera cases in the affected African countries decline, heavy flooding due to seasonal rains and tropical cyclones in southern Africa are raising the risk of the disease spreading and threatening to undermine outbreak control efforts.
:: 28 February 2023  **Community-based response boosts Liberia’s COVID-19 detection, vaccination drive**
:: 27 February 2023  **Mozambique targets 720 000 people in cholera vaccination drive**

**WHO Region of the Americas** PAHO
:: 02 March 2023  **Onchocerciasis or "river blindness" - a disease that affects the poorest in rural areas**
February 24, 2023 (PAHO) — Onchocerciasis is a parasitic disease caused by tiny worms that can lead to skin and eye damage, including irreversible blindness. Following decades of concerted action spurred by the Pan American Health Organization (PAHO) and its partners, the region of the Americas has largely eliminated the disease, with remaining...

**WHO South-East Asia Region** SEARO
No new digest content identified.

**WHO European Region** EURO
:: 1 March 2023  **Maternal mortality rates stagnate in some countries in Europe despite recent progress, new data warn**
:: 1 March 2023  **First-of-its-kind WHO/Europe course puts health workforce and leadership at the heart of health system recovery**
:: 1 March 2023  **Using data to provide more specialized health care in Ukraine**

**WHO Western Pacific Region**
No new digest content identified.

::::::

**Disease Outbreak News (DONs)**
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

26 February 2023  | **Avian Influenza A (H5N1) - Cambodia**
New WHO Publications
https://www.who.int/publications/index
3 March 2023
Understanding the global measure of primary health care expenditure

2 March 2023
Promoting the health of refugees and migrants: experiences from around the world
Overview
This publication is a compendium of 49 country examples highlighting efforts in improving refugees’ and migrants’ health following the adoption of the WHO Global Action Plan on Promoting the health of refugees and migrants at the seventy-second World Health Assembly, in May 2019.

1 March 2023
Integrating health in urban and territorial planning: a sourcebook

CDC/ACIP [U.S.] [to 04 Mar 2023]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases
No new digest content identified.

ACIP Meetings
Next ACIP Meeting: June 21-22

MMWR Weekly
March 3, 2023 / No. 9
PDF of this issue
- Possible Undetected Mpox Infection Among Persons Accessing Homeless Services and Staying in Encampments — San Francisco, California, October–November 2022
- Interim Clinical Treatment Considerations for Severe Manifestations of Mpox — United States, February 2023

Coronavirus Disease 2019 (COVID-19)- CDC
Announcements/reports/data summaries.
3/1/23
**Overall US COVID-19 Vaccine Distribution and Administration Update as of Wed, 01 Mar 2023 06:00:00 EST**

---

**Africa CDC** [to 04 Mar 2023]
http://www.africacdc.org/
Press Releases
**GSMA signs agreement with Africa Centres for Disease Control and Prevention, to harness the power of mobile to combat disease in Africa**
4 March 2023

**Africa CDC in collaboration with Institut Pasteur de Dakar (IPD) organized a training on Molecular Diagnosis of Marburg Virus**
27 February 2023

---

**China CDC**
http://www.chinacdc.cn/en/

**National Health Commission of the People's Republic of China** [to 04 Mar 2023]
http://en.nhc.gov.cn/
News
*Website not responding at inquiry*
*[Editor’s Note: The most recent post on this site is 24 Dec 2022, representing the last daily report on confirmed COVID-19 infections.]*

**National Medical Products Administration – PRC** [to 04 Mar 2023]
http://english.nmpa.gov.cn/
No new digest content identified.

**China CDC Weekly Reports: Current Volume (5)**
2023-03-03 / No. 9  WOMEN HEALTH ISSUE
[View PDF of this issue]
- Preplanned Studies: Knowledge of Cervical Cancer and HPV, and Willingness to Receive HPV Vaccination Among 20–45-Year-Old Women — Six Provinces, China, 2018

---

**Organization Announcements**

**Paul G. Allen Frontiers Group** [to 04 Mar 2023]
https://alleninstitute.org/news-press/
BMGF - Gates Foundation [to 04 Mar 2023]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 04 Mar 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
News: Articles and Publications
No new digest content identified.

CARB-X [to 04 Mar 2023]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 04 Mar 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – March 2023 is now posted here

CEPI – Coalition for Epidemic Preparedness Innovations [to 04 Mar 2023]
http://cepi.net/
Latest News
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 04 Mar 2023]
https://cioms.ch/
News; Publications; Events
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 04 Mar 2023]
https://www.darpa.mil/news
News
No new digest content identified.

**Duke Global Health Innovation Center** [to 04 Mar 2023]
https://dukeghic.org/
Our Blog
No new digest content identified.

**EDCTP** [to 04 Mar 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
28 February 2023
**Call for nominations EDCTP prizes 2023**

**Emory Vaccine Center** [to 04 Mar 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

**European Vaccine Initiative** [to 04 Mar 2023]
http://www.euvaccine.eu/
Latest News, Events
News, Events
No new digest content identified.

**Evidence Aid** [to 04 Mar 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
No new digest content identified.

**Fondation Merieux** [to 04 Mar 2023]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.
Unitaid and the Global Health Innovative Technology Fund strengthen ties to improve access to critical health tools

February 28, 2023

The partnership will focus on tackling complex challenges such as emerging drug resistance in tuberculosis (TB) and malaria and shifting patterns of vector-borne diseases due to climate change.
**IAVI** [to 04 Mar 2023]
https://www.iavi.org/
*LATEST NEWS*
March 2, 2023
**IAVI and BARDA expand partnership to advance IAVI’s filovirus vaccine candidates**
IAVI announced today the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, funded additional development and testing of IAVI’s single-dose vaccine candidates against the filoviruses Marburg virus (MARV) and Sudan ebolavirus (SUDV).
BARDA’s US$30 million award to IAVI expands the agency’s existing support of IAVI’s SUDV vaccine candidate and is in addition to a 2022 option under the initial award of $17 million to advance IAVI’s MARV vaccine candidate into clinical trials. Filoviruses can cause severe hemorrhagic fever outbreaks and continue to impact the health security and geopolitical stability of Central and Western Africa...

**ICRC** [to 015 Oct 2022]
*What’s New [Selected]*
**Haiti: urgent call for the protection of the medical mission, humanitarian access and respect for the Red Cross emblem**
People who are ill or injured must be allowed to seek medical attention freely, without discrimination, at all times and in all circumstances. Health-care workers, and medical vehicles and facilities must never be hindered in their work to prevent and... 03-03-2023 | News release

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
*Selected Statements, Press Releases, Research*
No new digest content identified.

**IFFIm**
http://www.iffim.org/
*Press Releases/Announcements*
**How Uzbekistan scrambled to stay polio-free - and succeeded**
17 Feb 2023
Still endemic to neighbouring Afghanistan, polio was suddenly resurging in next-door Tajikistan. Uzbekistan’s health system needed to act fast, or risk the futures of its children.

**IFRC** [to 04 Mar 2023]
*Press Releases [Selected]*
No new digest content identified.
Institut Pasteur  [to 04 Mar 2023]
Press Documents
No new digest content identified.

ISC / International Science Council  [to 04 Mar 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Latest Updates
No new digest content identified.

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC  [to 04 Mar 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI  [to 04 Mar 2023]
http://www.ivi.int/
IVI News & Announcements
Webinar - Vaccines and AMR: Considerations for AMR Policy and Practice in Low- and Middle-Income Countries
23 Mar 2023

Johns Hopkins Center for Health Security  [to 04 Mar 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News  [Selected]
No new digest content identified.

MSF/Médecins Sans Frontières  [to 04 Mar 2023]
http://www.msf.org/
Latest [Selected Announcements]
Epidemics and pandemics
MSF statement on WHO negotiating body meeting on pandemic prevention, prepa... Speech 28 Feb 2023
National Academy of Medicine - USA [to 04 Mar 2023]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 04 Mar 2023]
News
Research and Higher Education Institutions in the Next 75 Years ' Symposium Proceedings
February 28, 2023
The National Academies of Sciences Engineering and Medicine have released a new proceedings of a symposium that explored how research and higher education institutions should transform in the next 75 years to better address complex global challenges such as responding to pandemics advancing innovation and building and nurturing research capacity.

National Vaccine Program Office - U.S. HHS [to 04 Mar 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No new digest content identified.

PATH [to 04 Mar 2023]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Rockefeller Foundation [to 04 Mar 2023]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
No new digest content identified.

Sabin Vaccine Institute [to 04 Mar 2023]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS [to 04 Mar 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
1 March 2023
How harsh drug laws undermine health and human rights in Asia Pacific
28 February 2023

“Silence is better” — How the criminalisation of sex workers keeps exploitation in the shadows

UNICEF [to 04 Mar 2023]
https://www.unicef.org/media/press-releases
Remarks
Press release
28 February 2023
Number of children without critical social protection increasing globally

GENEVA/NEW YORK, 1 March 2023 - The number of children without access to social protection is increasing year-on-year, leaving them at risk of poverty, hunger and discrimination, according to a new report released by the International Labour Organization (ILO) and UNICEF today. More than a billion reasons: The urgent need to build universal social...

Press release
28 February 2023
2.5 million children in Türkiye need urgent humanitarian assistance, says UNICEF Executive Director, following two-day visit to Türkiye

ANKARA, 28 February 2023 – UNICEF Executive Director Catherine Russell today concluded a two-day visit to Türkiye, where she met with children and families affected by the powerful earthquakes that hit southeast Türkiye and northern Syria earlier this month. Russell highlighted the importance of social services, including water and sanitation, and...

Unitaid [to 04 Mar 2023]
https://unitaid.org/
Featured News
02 March 2023
Nearly three-quarters of a million young lives saved as seasonal malaria chemoprevention marks 10 years since start of first pilots

28 February 2023
Unitaid and the Global Health Innovative Technology Fund strengthen ties to improve access to critical health tools

Vaccine Equity Cooperative [nee Initiative] [to 04 Mar 2023]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.
Wellcome Trust  [to 04 Mar 2023]
https://wellcome.ac.uk/news
News, Opinion, Reports
News
**Wellcome’s response to the Independent Review of Research Bureaucracy**
This is our response to the review, led by Professor Adam Tickell, which set out findings and recommendations to reduce bureaucracy in research.
27 February 2023

The Independent Review of Research Bureaucracy, led by Professor Adam Tickell, is a timely and welcome report on the current status of bureaucracy in the UK research funding system. Overall, Wellcome is supportive of the seven principles the report recommends should underly the future direction of research bureaucracy. However, for funders specifically, reduction in bureaucracy must be balanced against their right and duty to ensure the substantial funds they award are disbursed and protected appropriately. Our aim is to balance sometimes competing needs to ensure unnecessary bureaucracy does not hamper researchers and organisations from making progress towards achieving our combined strategic objectives.

The report has many important recommendations for government funders in particular, and we look forward to the Government’s response to the report. There are also relevant messages for the sector as a whole and in our response below we focus on the specific recommendations most relevant to Wellcome...

The Wistar Institute  [to 04 Mar 2023]
Media
No new digest content identified.
WFPHA: World Federation of Public Health Associations  [to 04 Mar 2023]
https://www.wfpha.org/
Latest News - Blog
Welcoming the New Co-Chair of Our Public Health in Emergencies and Disasters Working Group
Mar 2, 2023
A warm welcome to Colette Cunningham for joining our family as Co-Chair of the Public Health in Emergencies and Disasters Working Group.

World Medical Association [WMA]  [to 04 Mar 2023]
Press Releases
02.03.2023
Global Medical and Human Rights Groups Call on Türkiye to End Persecution of Doctors
In a letter issued today, four international medical and human rights organisations call on Turkish authorities to drop the baseless charges against the leadership of the Turkish Medical Association (TMA) at a time when doctors are urgently needed to tend to victims of the 6 February earthquake that have caused over 45,000 deaths in Türkiye and Syria.

World Organisation for Animal Health (OIE)  [to 04 Mar 2023]
https://www.oie.int/en/
Press Releases, Statements
No new digest content identified.

:::::::

ARM [Alliance for Regenerative Medicine]  [to 04 Mar 2023]
Selected Press Releases
No new digest content identified.

BIO  [to 04 Mar 2023]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 04 Mar 2023]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations  [to 04 Mar 2023]
https://internationalbiotech.org/news/
No new digest content identified.

IFPMA  [to 04 Mar 2023]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
Statement  28 Feb 2023
Industry statement at fourth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response
On 28 February, IFPMA delivered a statement at the fourth meeting of the Intergovernmental Negotiating Body (INB) for a WHO instrument on pandemic prevention, preparedness and response held from 27 February - 3 March 2023.

International Alliance of Patients’ Organizations – IAPO  [to 04 Mar 2023]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest announcements identified.

PhRMA  [to 04 Mar 2023]
http://www.phrma.org/
Press Releases
No new digest announcements identified.

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases  - No new digest announcements identified

Bharat Biotech
Press Releases  - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias  - Website not responding at inquiry

Biological E
News  - No new digest announcements identified
BioNTech
Press Releases
1 March 2023
**BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel**

1 March 2023

Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media
01 March 2023
**US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate**

Committee votes unanimously that the data support the effectiveness of the vaccine and 10-2 that the data support the safety of the vaccine

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Merck
News releases - No new digest announcements identified
Moderna
*Press Releases* - No new digest announcements identified

Nanogen
*News* - No new digest announcements identified

Novartis
*News* - No new digest announcements identified

Novavax
*Press Releases* - No new digest announcements identified

Pfizer
*Recent Press Releases*
03.01.2023 VaccinesCovid-19Vaccines

02.28.2023
**Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults**

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
*Press Releases* - No new digest announcements identified

Serum Institute of India
*NEWS & ANNOUNCEMENTS* - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
*News* - No new digest announcements identified

Sinovac
*Press Releases* - No new digest announcements identified

SK Biosciences
*Press Releases*
**SK bioscience’s Shingles Vaccine Secures the Highest Market Share in South Korea**
- ‘SKYZoster®, ’ the world second developed shingles vaccine secures 54% of the South Korean m...
2023. 02. 28
Valneva
Press Releases
March 2, 2023
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
....As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership[1]. It is, however, completing remaining clinical studies and submissions as agreed with regulators.

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]  
[No website identified]

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Journal Watch
Journal Watch continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 14, 2023  Issue 1
https://www.tandfonline.com/toc/uabr21/current
Clinicians in Government

Clinicians serving in federal or state government in the United States are accountable to patients, the public, and their professions in ways that transcend clinicians’ typical duties to individual patients and colleagues and even transcend their fiduciary duties to society. One reason for this is that, when clinicians draw upon their professional skill sets to help administer agencies, make laws, or enforce regulations, the social and cultural power they wield as professionals is reified with political power and authority of the state. Clinician governors’ legal and ethical responsibilities extend to preparing, building, and maintaining health sector capacity to deliver quality services equitably in the best of times and during crises. Our lives often depend on how fully clinician governors’ offices are respected and how competently and efficiently their roles are executed.

American Journal of Infection Control

Major Articles
SARS-CoV-2 antigen rapid tests and universal screening for COVID-19 Omicron variant among hospitalized children
Kai-Qian Kam, Matthias Maiwald, Chia Yin Chong,...
Published online: November 08, 2022
p255-260

Brief Reports
Influenza vaccination for hospital Employees: A 3-year success-story of a flu-pod drive-thru at a Veterans affairs medical center
Lisa Bailey, Aikaterini Papamanoli, Monique Thorne, ...
Published online: July 28, 2022
p346-348

Commentaries
COVID-19 pandemic relief funding—a lifeline for equity
Jaeh Kim, Jaejeong Kim, Simar S. Bajaj, Fatima Cody Stanford
Published online: October 13, 2022
p354-355

Highlights
- Funding for federal COVID-19 relief programs has run out since March 2022, resulting in the suspension of the Provider Relief Fund and the Uninsured Program.
- These funding cuts have resulted in a backslide in pandemic protection, with disproportionate effects on the most vulnerable Americans.
- Suspension of COVID-19 relief programs particularly risks derailing long-standing efforts to build trust and healthcare access among marginalized communities.
Impacts of the COVID-19 Pandemic on Nationwide Chronic Disease Prevention and Health Promotion Activities
Lilanthi Balasuriya, Peter A. Briss, Evelyn Twentyman, ...
Published online: October 16, 2022
p452-458

NOTES FROM THE FIELD
A Community-Engaged Social Marketing Campaign to Promote Equitable Access to COVID-19 Services Among Latino Immigrants
113(3), pp. 263–266

CHALLENGES TO PUBLIC HEALTH LAW IN THE AFTERMATH OF COVID-19
State Public Health Emergency Powers in Response to COVID-19
James G. Hodge, Lauren T. Dunning and Jennifer L. Piatt

COVID-19, Injury/Emergency Care/Violence, Health Policy, Health Law, Epidemiology, Health Administration, Research Article
Elizabeth Platt, Katie Moran-McCabe, Amy Cook and Scott Burris

Tan Luong, et al.
Volume/Issue: Volume 108: Issue 3
Article Category: Research Article
DOI: https://doi.org/10.4269/ajtmh.22-0384
Page(s): 492–502

A Methodological Framework for Economic Evaluation of Operational Response to Vector-Borne Diseases Based on Early Warning Systems
Building autonomous systems for deployment in the open world has been a longstanding objective in both artificial intelligence and robotics. The open world, however, presents challenges that question some of the assumptions often made in contemporary AI models. Autonomous systems that operate in the open world face complex, non-stationary environments wherein enumerating all situations the system may face over the course of its deployment is intractable. Nevertheless, these systems are expected to operate safely and reliably for extended durations. Consequently, AI systems often rely on some degree of human assistance to mitigate risks while completing their tasks, and are hence better treated as semi-autonomous systems. In order to reduce unnecessary reliance on humans and optimize autonomy, we propose a novel introspective planning model—competence-aware systems (CAS)—that enables a semi-autonomous system to reason about its own competence and allowed level of autonomy by leveraging human feedback or assistance. A CAS learns to adjust its level of autonomy based on experience and interactions with a human authority so as to reduce improper reliance on the human and optimize the degree of autonomy it employs in any given circumstance. To handle situations in which the initial CAS model has insufficient state information to properly discriminate feedback received from humans, we introduce a methodology called iterative state space refinement that gradually increases the granularity of the state space online. The approach exploits information that exists in the standard CAS model and requires no additional input from the human. The result is an agent that can more confidently predict the correct feedback from the human authority in each level of autonomy, enabling it learn its competence in a larger portion of the state space.
Effect of anxiety and depression on self-reported adverse reactions to COVID-19 vaccine: a cross-sectional study in Shanghai, China

The association of anxiety and depression with adverse reactions after receipt of coronavirus disease 2019 (COVID-19) vaccine is not clear among the general population. This study aims to evaluate the effect of... 

Authors: Zhitong Zhou, Junwei Shen, Miaomiao Zhao, Xiaoying Zhang, Tao Wang, Jue Li and Xudong Zhao

Citation: BMC Public Health 2023 23:425
Content type: Research Published on: 3 March 2023
Public health emergency preparedness for infectious disease emergencies: a scoping review of recent evidence

The COVID-19 pandemic continues to demonstrate the risks and profound health impacts that result from infectious disease emergencies. Emergency preparedness has been defined as the knowledge, capacity and orga...

Authors: Jessica M Lee, Rachel Jansen, Kate E Sanderson, Fiona Guerra, Sue Keller-Olaman, Michelle Murti, Tracey L O'Sullivan, Madelyn P Law, Brian Schwartz, Laura E Bourns and Yasmin Khan

Citation: BMC Public Health 2023 23:420
Content type: Research Published on: 2 March 2023

The global dynamic transmissibility of COVID-19 and its influencing factors: an analysis of control measures from 176 countries

To summarise the dynamic characteristics of COVID-19 transmissibility; To analyse and quantify the effect of control measures on controlling the transmissibility of COVID-19; To predict and compare the effecti...

Authors: Hongjian Wang and Yajia Lan

Citation: BMC Public Health 2023 23:404
Content type: Research Published on: 28 February 2023

Ethnic disparities in COVID-19 outcomes: a multinational cohort study of 20 million individuals from England and Canada

Heterogeneous studies have demonstrated ethnic inequalities in the risk of SARS-CoV-2 infection and adverse COVID-19 outcomes. This study evaluates the association between ethnicity and COVID-19 outcomes in tw...

Authors: Francesco Zaccardi, Pui San Tan, Baiju R. Shah, Karl Everett, Ash Kieran Clift, Martina Patone, Defne Saatci, Carol Coupland, Simon J. Griffin, Kamlesh Khunti, Hajira Dambha-Miller and Julia Hippisley-Cox

Citation: BMC Public Health 2023 23:399
Content type: Research Published on: 27 February 2023

COVID-19 vaccination coverage in Egypt: a large-scale national survey – to help achieving vaccination target, March-May, 2022

Only 57 countries have vaccinated 70% of their population against COVID-19, most of them in high-income countries, whereas almost one billion people in low-income countries remained unvaccinated. In March–May ... Authors: Amr Kandeel, Ibrahim Eldeyahy, Hanaa Abu ElSood, Manal Fahim, Salma Afifi, Shaimaa Abu Kamar, Hala BahaaEldin, ElSabah Ahmed, Amira Mohsen and Khaled Abdelghaffar

Citation: BMC Public Health 2023 23:397
Content type: Research Published on: 27 February 2023

Impact of the COVID-19 pandemic on maternal mental health, early childhood development, and parental practices: a global scoping review

In March 2020, the COVID-19 outbreak was declared a pandemic by the World Health Organization (WHO), generating stark economic and social repercussions that directly or indirectly affected families’ wellbeing ...
Authors: Ana Luiza Penna, Camila Machado de Aquino, Maria Suely Nogueira Pinheiro, Rodrigo Leão Ferreira do Nascimento, Simone Farias-Antúnez, David Augusto Batista Sá Araújo, Carol Mita, Marcia Maria Tavares Machado and Marcia C. Castro
Citation: BMC Public Health 2023 23:388
Content type: Research Published on: 24 February 2023

**BMC Research Notes**
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 04 Mar 2023)
[No new digest content identified]

**BMJ Evidence-Based Medicine**
February 2023 - Volume 28 - 1
https://ebm.bmj.com/content/28/1
[Reviewed earlier]

**BMJ Open**
January 2023 - Volume 13 - 1
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]

**Bulletin of the World Health Organization**
Volume 101(3); 2023 Mar 1
https://www.ncbi.nlm.nih.gov/pmc/issues/429599/
*Editorials*
**Resilience to emergencies and civil society organizations**
Hanna Teräsi, Nellie Kartoglu
doi: 10.2471/BLT.22.289237
PMCID: PMC9948501

*Research*
**Implementation of targeted cholera response activities, Cameroon**
doi: 10.2471/BLT.22.288885
PMCID: PMC9948504

**Implementation of a tuberculosis elimination project, India 2018–2019**
Aakshi Kalra, Akhil S ThekkePurakkal, Raghuram Rao, Debadutta Parija, Vaibhav Ghule, Ajaz Lone, Tajamul Showket, Rajendra P Joshi, Sanjay Sarin, Sarabjit S Chadha
**Cell**

Mar 02, 2023  Volume 186  Issue 5  p893-1086
https://www.cell.com/cell/current

*Commentary*

**Trustworthiness matters: Building equitable and ethical science**
Jenny Reardon, et al.

Trustworthy science requires research practices that center issues of ethics, equity, and inclusion. We announce the Leadership in the Equitable and Ethical Design (LEED) of Science, Technology, Mathematics, and Medicine (STEM) initiative to create best practices for integrating ethical expertise and fostering equitable collaboration.

*Featured Article*

**Whole-genome sequencing reveals a complex African population demographic history and signatures of local adaptation**
Shaohua Fan, et al.

Fan et al. studied the complex demographic history and the genetic basis of local adaptation for traits related to skin color, immune response, and metabolic processes across African populations using high-coverage whole-genome sequencing data of 180 individuals from 12 indigenous African populations.

**Child Care, Health and Development**

Volume 49, Issue 2  Pages: 211-406  March 2023
https://onlinelibrary.wiley.com/toc/13652214/current

[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**

Volume 113, Issue 3  Pages: 447-745  March 2023
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

*Editorial  Free Access*

**Diversity, Equity, and Inclusion: Translating Clinical Pharmacology for All**
Karthik Venkatakrishnan, Karen E. Brown, Kathleen M. Giacomini, Piet H. van der Graaf
Pages: 457-461
First Published: 16 February 2023

*Perspectives*

**Promoting Pharmacogenomics in Africa: Perspectives From Variation in G6PD and Other Pharmacogenes**
Blessing R. Sitabule, Houcemeddine Othman, Ananyo Choudhury, David Twesigomwe, Neil A. Hanchard
Pages: 476-479
First Published: 28 December 2022
Reviews  White Paper
Open Access

**Enhancing Diversity and Inclusion in Clinical Trials**
Amy Corneli, Emily Hanlen-Rosado, Kevin McKenna, Richardae Araojo, Dawn Corbett, Kaveeta Vasish, Bernadette Siddiqi, Tesheia Johnson, Luther T. Clark, Sara B. Calvert
Pages: 489-499
First Published: 11 January 2023

**State of the Art**

**Disruptive Innovations to Achieve Health Equity Through Healthcare and Research Transformation**
Sherita Hill Golden
Pages: 500-508
First Published: 05 December 2022
Open Access

**Beyond the Individual: Community-Centric Approaches to Increase Diversity in Biomedical Research**
Karen E. Brown, Alison E. Fohner, Erica L. Woodahl
Pages: 509-517
First Published: 30 November 2022
Open Access

**A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access**
Shalini V. Mohan, Jamie Freedman
Pages: 518-527
First Published: 19 December 2022

Clinical Therapeutics
January 2023  Volume 45  Issue 1  p1-88
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 20 Issue 1, February 2023
https://journals.sagepub.com/toc/ctja/20/1
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 04 Mar 2023]
[No new digest content identified]
The CRISPR Journal
Volume 6, Issue 1 / February 2023
https://www.liebertpub.com/toc/crispr/6/1
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
[Reviewed earlier]

Current Opinion in Infectious Diseases
February 2023 - Volume 36 - Issue 1
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 23, Issue 1 Pages: 1-87 March 2023
https://onlinelibrary.wiley.com/toc/14718847/current

ORIGINAL ARTICLES
Global sharing of COVID-19 vaccines: A duty of justice, not charity
Nancy S. Jecker
Pages: 5-14
First Published: 08 January 2022

Responsibility and vaccine nationalism in the Israeli-Palestinian conflict
Zohar Lederman, Ghada Majadli, Shmuel Lederman
Pages: 15-22
First Published: 18 January 2022

Challenges and practices arising during public health emergencies: A qualitative survey on ethics committees
Perihan Elif Ekmekci, Müberra Devrim Güner, Banu Buruk, Begüm Güneş, Berna Arda, Şefik Görkey
Pages: 23-33
Charity or empowerment? The role of COVAX for low and middle-income countries
Felicitas Holzer, Tania Manríquez Roa, Federico Germani, Nikola Biller-Andorno, Florencia Luna
Pages: 59-66
First Published: 20 March 2022

Development in Practice
Volume 33, Issue 1, 2023
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Development Policy Review
Volume 41, Issue 2 March 2023
https://onlinelibrary.wiley.com/toc/14677679/current
[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 2 Pages: 245-542 April 2023
Papers
Open Access
Rumour spread and control during the West African Ebola epidemic in Liberia
Monique Mitchell Turner, Skylar Lisse, Rajiv Rimal, Tamah Kamlem, Hina Shaikh, Nilakshi Biswas
Pages: 346-365
First Published: 28 June 2022

Flattening the curve: voluntary association participation and the 2013–16 West Africa Ebola epidemic
Michelle Reddy
Pages: 366-388
First Published: 25 May 2022

Ebola, informal settlements, and the role of place in infectious disease vulnerability: evidence from the 2014–16 outbreak in urban Sierra Leone
S. Harris Ali, Abu Conteh, Joseph Mustapha Macarthy, Alpha Sesay, Victoria Nancy Blango, Zuzana Hrdličková
Pages: 389-411
EMBO Reports
Volume 24  Issue 2  6 February 2023
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 29, Number 1—January 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 42  March 2023
[Reviewed earlier]

Epidemiology and Infection
Volume 151 - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 45, Issue 1  Pages: 1-38  January–February 2023
https://onlinelibrary.wiley.com/toc/25782363/current
Ancillary-care obligations - Evaluating public policy interventions
[Reviewed earlier]

Ethics & International Affairs
Winter 2022 (36.4)  December 21, 2022
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 26  February 2023
[Reviewed earlier]

The European Journal of Public Health
Volume 33, Issue 1, February 2023
Expert Review of Vaccines  
Vol 22 (1) 2023  Issue In Progress  
https://www.tandfonline.com/toc/ierv20/current  
[Reviewed earlier]

Foreign Affairs  
Volume 102, Number 1  January/February 2023  
https://www.foreignaffairs.com/issues/2023/102/1  
[No new digest content identified]

Forum for Development Studies  
Volume 49, 2022 - Issue 3  
http://www.tandfonline.com/toc/sfds20/current  
[Reviewed earlier]

Genetics in Medicines  
Volume 25, Issue 2  February 2023  
[Reviewed earlier]

Genome Medicine  
https://genomemedicine.biomedcentral.com/articles  
[Accessed 04 Mar 2023]  
[No new digest content identified]

Global Health Action  
Volume 16, Issue 1 (2023)  
https://www.tandfonline.com/toc/zgha20/current?nav=tocList  
[Reviewed earlier]

Global Health: Science and Practice (GHSP)  
Vol. 11, No. 1  February 28, 2023  
http://www.ghspjournal.org/content/current  
COMMENTARIES  
Oxygen Inequity in the COVID-19 Pandemic and Beyond  
Madeline Ross and Sarah K. Wendel  
Our review of recent publications on medical oxygen availability during the COVID pandemic underscores the urgent need to prevent unnecessary morbidity and mortality resulting from inequitable access to supplemental medical oxygen therapy.

FIELD ACTION REPORTS
Open Access
Design, Development, and Deployment of an Electronic Immunization Registry: Experiences From Vietnam, Tanzania, and Zambia
Emily Carnahan, Linh Nguyen, Sang Dao, Masaina Bwakya, Hassan Mtenga, Hong Duong, Francis Dien Mwansa, Ngwegwe Bulula, Huyen Dang, Maya Rivera, Trung Nguyen, Tuan Ngo, Doan Nguyen, Laurie Werner and Nga Nguyen
We compare experiences implementing electronic immunization registries across countries to highlight findings and recommendations related to time, partnerships, financial costs, and technology and infrastructure.

REVIEW
Open Access
Community Health Workers as Vaccinators: A Rapid Review of the Global Landscape, 2000–2021
Emily Gibson, Mariam Zameer, Rebecca Alban and Luc Mahougbé Kouwanou
This review identifies countries where community health workers administered vaccines and synthesizes health systems factors that may contribute to or detract from the feasibility of community health workers administering vaccines to alleviate health workforce shortages.

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 04 Mar 2023]
[No new digest content identified]

Global Public Health
Volume 18, Issue 1 (2023)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 04 Mar 2023]
[No new digest content identified]

Health and Human Rights
Volume 24, Issue 2, December 2022
Special Section: COVID-19 Vaccine Equity and Human Rights
[Reviewed earlier]

Health Economics, Policy and Law
Volume 18 - Issue 1 - January 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 38, Issue 2, March 2023
https://academic.oup.com/heapol/issue/38/2
[New issue; No digest content identified]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 04 Mar 2023]
[No new digest content identified]

Human Gene Therapy
Volume 34, Issue 3-4 / February 2023
https://www.liebertpub.com/toc/hum/34/3-4
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

Immunity
Feb 14, 2023  Volume 56  Issue 2  p225-458
https://www.cell.com/immunity/current
[Reviewed earlier]
Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 04 Mar 2023]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 04 Mar 2023]
[No new digest content identified]

International Health
Volume 15, Issue 1, January 2023
https://academic.oup.com/inthealth/issue/15/1
[Reviewed earlier]

International Human Rights Law Review
Volume 11 (2022): Issue 2 (Dec 2022)
https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol. 10 No. 3 (2023): March 2023
Original Research Articles
Analysis of community acceptability to COVID-19 vaccination in coastal communities of North Minahasa Regency
Grace D. Kandou, Budi T. Ratag, Angela F. C. Kalesaran, Priscilla C. Kandou
901-905
DOI: 10.18203/2394-6040.ijcmph20230332

Factors associated with full immunization coverage among under-2 years children in Nepal
Salina Thapa, Pramodh Chaudhary, Raj Kumar Sangroula, Arati Dhoju Shrestha, Pabitra Balampaki Balmampki, Janak Kumar Thapa
943-950
DOI: 10.18203/2394-6040.ijcmph20230605

Clinical course, complications, immunization status and outcome of mumps in children
Naseer Yousuf Mir, Jawad Nazir Wani, Wamiq Farooq, Bashir U. Zaman
1076-1080
DOI: 10.18203/2394-6040.ijcmph20230619

Hepatitis B vaccination status and knowledge, attitude, and practice of hepatitis B among medical students at a medical college in central India
Research Letter

Measles Serostatus Among Parturient Patients at 2 Philadelphia Hospitals in 2021

This observational study explores whether rubella serostatus, which is routinely assessed during pregnancy, can serve as a proxy for measles serostatus in parturient persons.

Editorial

Nonhuman “Authors” and Implications for the Integrity of Scientific Publication and Medical Knowledge
Annette Flanagin, RN, MA; Kirsten Bibbins-Domingo, PhD, MD, MAS; Michael Berkwits, MD, MSCE; et al. free access JAMA. 2023;329(8):637-639. doi:10.1001/jama.2023.1344

JAMA Health Forum
February 2023, Vol 4, No. 2 https://jamanetwork.com/journals/jama-health-forum/issue [Reviewed earlier]

JAMA Pediatrics

International Journal of Human Rights in Healthcare
Volume 15 Issue 3, 2022 https://www.emerald.com/insight/publication/issn/2056-4902/vol/15/iss/3 Special Issue: Children, young people and their international human right to healthcare [Reviewed earlier]
JBI Evidence Synthesis
February 2023 - Volume 21 - Issue 2
https://journals.lww.com/jbisrIR/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
February 2023  Volume 72  Issue 2  p161-314
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health
Volume 48, issue 1, February 2023
https://link.springer.com/journal/10900/volumes-and-issues/48-1
[Reviewed earlier]

Journal of Development Economics
Volume 161  March 2023
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 5, December 2022
http://journals.sagepub.com/toc/jre/current
Ethical Issues using Digital Surveillance Technologies in Research
[Reviewed earlier]

Journal of Epidemiology & Community Health
March 2023 - Volume 77 - 3
https://jech.bmj.com/content/77/3
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 15, Issue 4  Pages: 315-424  December 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

**Journal of Global Ethics**  
Volume 18, Issue 3, 2022  
[http://www.tandfonline.com/toc/rjge20/current](http://www.tandfonline.com/toc/rjge20/current)  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**  
Volume 34, Number 1, February 2023  
[https://muse.jhu.edu/issue/49033](https://muse.jhu.edu/issue/49033)  
*Table of Contents*  
[Reviewed earlier]

**Journal of Immigrant and Minority Health**  
Volume 25, issue 1, February 2023  
*Contents*  
[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**  
Volume 21, 2023 _ Issue 1  
[https://www.tandfonline.com/toc/wimm20/current](https://www.tandfonline.com/toc/wimm20/current)  
[Reviewed earlier]

**Journal of Infectious Diseases**  
Volume 227, Issue 3, 1 February 2023  
[https://academic.oup.com/jid/issue/227/3](https://academic.oup.com/jid/issue/227/3)  
[Reviewed earlier]

**Journal of International Development**  
Volume 35, Issue 1 _ Pages: 1-197_ January 2023  
[Reviewed earlier]

**Journal of Medical Ethics**  
February 2023 - Volume 49 - 2  
[http://jme.bmj.com/content/current](http://jme.bmj.com/content/current)  
[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**
Journal of Pediatrics
January 2023  Volume 252  p1-226
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 04 Mar 2023]
[Reviewed earlier]

Journal of Public Health Management & Practice
January/February 2023 - Volume 29 - Issue 1
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 4, December 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-4
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
March 2023  Volume 20  Issue 200
https://royalsocietypublishing.org/toc/rsif/current
[New issue; No digest content identified]

Journal of Travel Medicine
Volume 29, Issue 8, December 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
The Lancet

Mar 04, 2023  Volume 401  Number 10378  p705-794
https://www.thelancet.com/journals/lancet/issue/current

Editorial

A decisive moment for The World Bank
The Lancet

Viewpoint

After 2 years of the COVID-19 pandemic, translating One Health into action is urgent
Thierry Lefrançois, et al.

Introduction
The world is coping with the health, societal, and economic consequences of more than 2 years of the COVID-19 pandemic. Emerging diseases caused by new pathogens, or re-emerging infectious diseases, appear regularly and their frequency is increasing. Several research papers have shown that the cost of preventing an infectious disease is much lower than the cost of managing one, especially at a global level. A change in health-care framework is needed to improve pandemic prevention, which will require a global understanding of disease emergence and an integrated One Health approach. The environmental, social, economic, ethical, and political factors that characterise a social ecosystem and influence the emergence of zoonoses should be considered to control these emergences.

COVID-19 has exposed the disconnection between governmental promotion of the One Health approach in international arenas (eg, political conferences) and the reality outside of government spaces—with the absence of an efficient, comprehensive One Health surveillance system that could have been in place from the start of the pandemic. As members of France's COVID-19 Scientific Council appointed in March, 2020, to support governmental efforts in managing the COVID-19 pandemic, we had to contend with this negative reality. Based on our experience, we propose an ambitious roadmap to prevent and mitigate future pandemic crises, including real-life implementation of intersectoral activities and processes. Our strategy will require a new, worldwide, One Health vision that includes ambitious national and international initiatives, and One Health education and training...

Articles| Online First

Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
COVID-19 Forecasting Team †
Open Access  Published: February 16, 2023
DOI: https://doi.org/10.1016/S0140-6736(22)02465-5

Summary
Background
Understanding the level and characteristics of protection from past SARS-CoV-2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe disease is essential for predicting future potential disease burden, for designing policies that restrict travel or access to venues where there is a high risk of transmission, and for informing choices about when to receive vaccine doses. We
aimed to systematically synthesise studies to estimate protection from past infection by variant, and where data allow, by time since infection.

Methods

In this systematic review and meta-analysis, we identified, reviewed, and extracted from the scientific literature retrospective and prospective cohort studies and test-negative case-control studies published from inception up to Sept 31, 2022, that estimated the reduction in risk of COVID-19 among individuals with a past SARS-CoV-2 infection in comparison to those without a previous infection. We meta-analysed the effectiveness of past infection by outcome (infection, symptomatic disease, and severe disease), variant, and time since infection. We ran a Bayesian meta-regression to estimate the pooled estimates of protection. Risk-of-bias assessment was evaluated using the National Institutes of Health quality-assessment tools. The systematic review was PRISMA compliant and was registered with PROSPERO (number CRD42022303850).

Findings

We identified a total of 65 studies from 19 different countries. Our meta-analyses showed that protection from past infection and any symptomatic disease was high for ancestral, alpha, beta, and delta variants, but was substantially lower for the omicron BA.1 variant. Pooled effectiveness against re-infection by the omicron BA.1 variant was 45·3% (95% uncertainty interval [UI] 17·3–76·1) and 44·0% (26·5–65·0) against omicron BA.1 symptomatic disease. Mean pooled effectiveness was greater than 78% against severe disease (hospitalisation and death) for all variants, including omicron BA.1. Protection from re-infection from ancestral, alpha, and delta variants declined over time but remained at 78·6% (49·8–93·6) at 40 weeks. Protection against re-infection by the omicron BA.1 variant declined more rapidly and was estimated at 36·1% (24·4–51·3) at 40 weeks. On the other hand, protection against severe disease remained high for all variants, with 90·2% (69·7–97·5) for ancestral, alpha, and delta variants, and 88·9% (84·7–90·9) for omicron BA.1 at 40 weeks.

Interpretation

Protection from past infection against re-infection from pre-omicron variants was very high and remained high even after 40 weeks. Protection was substantially lower for the omicron BA.1 variant and declined more rapidly over time than protection against previous variants. Protection from severe disease was high for all variants. The immunity conferred by past infection should be weighed alongside protection from vaccination when assessing future disease burden from COVID-19, providing guidance on when individuals should be vaccinated, and designing policies that mandate vaccination for workers or restrict access, on the basis of immune status, to settings where the risk of transmission is high, such as travel and high-occupancy indoor settings.

Funding


The Lancet Child & Adolescent Health
Feb 2023 Volume 7 Number 2 p77-144, e2-e4
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Feb 2023 Volume 5 Number 2 e51-e101
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]
Nature Biotechnology
Volume 41 Issue 2, February 2023
https://www.nature.com/nbt/volumes/41/issues/2
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 04 Mar 2023)
[No new digest content identified]

Nature Genetics
Volume 55 Issue 2, February 2023
https://www.nature.com/ng/volumes/55/issues/2
[Reviewed earlier]

Nature Human Behaviour
Volume 7 Issue 2, February 2023
https://www.nature.com/nathumbehav/volumes/7/issues/2
[Reviewed earlier]

Nature Medicine
Volume 29 Issue 2, February 2023
https://www.nature.com/nm/volumes/29/issues/2
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 22 Issue 2, February 2023
https://www.nature.com/nrd/volumes/22/issues/2
[Reviewed earlier]

Nature Reviews Genetics
Volume 24 Issue 2, February 2023
https://www.nature.com/nrg/volumes/24/issues/2
[Reviewed earlier]

Nature Reviews Immunology
Volume 23 Issue 2, February 2023
https://www.nature.com/nri/volumes/23/issues/2
[Reviewed earlier]
**New England Journal of Medicine**  
March 2, 2023  Vol. 388 No. 9  
https://www.nejm.org/toc/nejm/medical-journal  

**Perspective**  
**Investing in National HIV PrEP Preparedness**  
J. Johnson, A. Killelea, and K. Farrow  769-771  

**Health Care Reform and Equity for Undocumented Immigrants — When Crisis Meets Opportunity**  
P.M.G. Santos, K. Shah, F.M. Gany, and F. Chino  771-773  

**npj Vaccines**  
https://www.nature.com/npjvaccines/  
[Accessed 04 Mar 2023]  
[No new digest content identified]  

**Pediatrics**  
Volume 151, Issue 2  February 2023  
https://publications.aap.org/pediatrics/issue/151/2  
[Reviewed earlier]  

**PharmacoEconomics**  
Volume 41, issue 2, February 2023  
[Reviewed earlier]  

**PLoS Biology**  
https://journals.plos.org/plosbiology/  
(Accessed 04 Mar 2023)  
[No new digest content identified]  

**PLoS Genetics**  
https://journals.plos.org/plosgenetics/  
(Accessed 04 Mar 2023)  
[No new digest content identified]  

**PLoS Medicine**  
http://www.plosmedicine.org/  
(Accessed 04 Mar 2023)  
[No new digest content identified]
PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 04 Mar 2023)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 04 Mar 2023]
Refusal to participate in research among hard-to-reach populations: The case of detained persons
Stéphanie Baggio, Leonel Gonçalves, Patrick Heller, Hans Wolff, Laurent Gétaz
Research Article | published 03 Mar 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0282083

Barriers and facilitators of vaccine hesitancy for COVID-19, influenza, and pertussis during pregnancy and in mothers of infants under two years: An umbrella review
Bethany Nichol, Jemma Louise McCready, Mary Steen, John Unsworth, Valentina Simonetti, Marco Tomietto
Research Article | published 02 Mar 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0282525

The institutional origins of vaccines distrust: Evidence from former-Soviet countries
Joan Costa-Font, Jorge Garcia-Hombrados, Anna Nicińska
Research Article | published 01 Mar 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0282420

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 04 Mar 2023]
[PLoS journal websites not responding at inquiry for recent articles]

PNAS - Proceedings of the National Academy of Sciences of the United States
February 28, 2023 vol. 120 no. 9
https://www.pnas.org/toc/pnas/120/9
[New issue; No digest content identified]

PNAS Nexus
Volume 2, Issue 2, February 2023
IN PROGRESS
https://academic.oup.com/pnasnexus/issue
[Reviewed earlier]
Prehospital & Disaster Medicine
Volume 38 - Issue 1 - February 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 167  February 2023
[Reviewed earlier]

Proceedings of the Royal Society B
22 February 2023  Volume 290  Issue 1993
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 214  Pages 1-180 (January 2023)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 3, November 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 138 Issue 1, January/February 2023
https://journals.sagepub.com/toc/phrg/138/1
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 3, February 2023
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 19 Issue 1, January 2023
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]
Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 04 Mar 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 43, Issue 1  Pages: 1-201  January 2023
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus with Evolving Perspectives
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 04 Mar 2023]
[No new digest content identified]

Science
Volume 379| Issue 6635| 3 Mar 2023
https://www.science.org/toc/science/current
Policy Forum
The growing influence of industry in AI research
BY Nur Ahmed, Muntasir Wahed, Neil C. Thompson
02 Mar 2023: 884-886
Abstract
For decades, artificial intelligence (AI) research has coexisted in academia and industry, but the balance is tilting toward industry as deep learning, a data-and-compute-driven subfield of AI, has become the leading technology in the field. Industry’s AI successes are easy to see on the news, but those headlines are the heralds of a much larger, more systematic shift as industry increasingly dominates the three key ingredients of modern AI research: computing power, large datasets, and highly skilled researchers. This domination of inputs is translating into AI research outcomes: Industry is becoming more influential in academic publications, cutting-edge models, and key benchmarks. And although these industry investments will benefit consumers, the accompanying research dominance should be a worry for policy-makers around the world because it means that public interest alternatives for important AI tools may become increasingly scarce.
**Vaccines for a sustainable planet**

BY Simone Pecetta...David Salisbury...Rino Rappuoli
01 Mar 2023
Free

Abstract
The health of the planet is one objective of the United Nations’ Sustainable Development Goals. Vaccines can affect not only human health but also planet health by reducing poverty, preserving microbial diversity, reducing antimicrobial resistance, and preventing an increase in pandemics that is fueled partly by climate change.

---

**Social Science & Medicine**
Volume 318  February 2023
[Reviewed earlier]

**Systematic Reviews**
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 04 Mar 2023]
[No new digest content identified]

**Theoretical Medicine and Bioethics**
Volume 44, issue 1, February 2023
https://link.springer.com/journal/11017/volumes-and-issues/44-1
[Reviewed earlier]

**Travel Medicine and Infectious Diseases**
Volume 51  January–February 2023
[Reviewed earlier]

**Tropical Medicine & International Health**
Volume 28, Issue 3  Pages: i-iv, 157-246  March 2023
https://onlinelibrary.wiley.com/toc/13653156/current
Selected Content

Review article  Open access
COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase vaccine compliance: A systematic narrative review and meta-analysis
Francesco Paolo Bianchi, Pasquale Stefanizzi, Andrea Martinelli, Nazario Brescia, Silvio Tafuri
Pages 1303-1309

Review article  Abstract only
The methodological quality of economic evaluations of measles outbreaks: A systematic review of cost-of-illness studies
Patricia Coelho de Souarez, Luciana Martins Rozman, Taiane Siraisi Fonseca, Pietro Rodrigo Borsari, ...
Ana Marli Christovam Sartori
Pages 1319-1332

Research article  Open access
School immunization coverage in adolescents during the COVID-19 pandemic: A retrospective cohort study
Hannah Sell, Yuba Raj Paudel, Donald Voaklander, Shannon E. MacDonald
Pages 1333-1341

Research article  Open access
Identifying intervention strategies to improve HPV vaccine decision-making using behaviour change theory
Sarah Marshall, Aoife Fleming, Laura J. Sahm, Anne C. Moore
Pages 1368-1377

Research article  Open access
A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country
Vianney Tricou, Susannah Eyre, Mahadev Ramjee, Paul Collini, ...
Derek Wallace
Pages 1398-1407

Research article  Full text access
COVID-19 vaccination hesitancy and uptake: Perspectives from people released from the Federal Bureau of Prisons
Camille Kramer, Minna Song, Ca

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 04 Mar 2023]
Latest Articles
[No new digest content identified]

Value in Health
February 2023  Volume 26  Issue 2  p151-316
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 06 Jan 2023]
Selected Research
[No new digest content identified]

medRxiv
https://www.medrxiv.org/content/about-medrxiv
[Accessed 06 Jan 2023]
[Filter: All articles]
Selected Research
Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of Long-Term Care Facilities in the VIVALDI study
Oliver Stirrup, Madhumita Shrotri, Natalie L. Adams, Maria Krutikov, Borscha Azmi, Igor Monakhov, Gokhan Tut, Paul Moss, Andrew Hayward, Andrew Copas, Laura Shallcross
medRxiv 2023.03.01.23286627; doi: https://doi.org/10.1101/2023.03.01.23286627

Mpx (monkeypox) knowledge, concern, willingness to change behaviour, and seek vaccination: Results of a national cross-sectional survey
James MacGibbon, Vincent Cornelisse, Anthony K J Smith, Timothy R Broady, Mohamed A Hammoud, Benjamin R Bavinton, Heath Paynter, Matthew Vaughan, Edwina J Wright, Martin Holt
medRxiv 2022.12.01.22282999; doi: https://doi.org/10.1101/2022.12.01.22282999 Revision
An assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexual and other men who have sex in the Netherlands
Philippe C.G. Adam, Eline L.M. Op de Coul, Paul Zantkuijl, Hanna Bos, Maria Xiridou, Cor Blom, Itsada Ketsuwan, Margreet J.M. te Wierik, Silke David, John B.F. de Wit
medRxiv 2023.02.28.23286578; doi: https://doi.org/10.1101/2023.02.28.23286578

Does ChatGPT Provide Appropriate and Equitable Medical Advice?: A Vignette-Based, Clinical Evaluation Across Care Contexts
Anthony J. Nastasi, Katherine R. Courtright, Scott D. Halpern, Gary E. Weissman
medRxiv 2023.02.25.23286451; doi: https://doi.org/10.1101/2023.02.25.23286451

ABSTRACT
ChatGPT is a large language model trained on text corpora and reinforced with human supervision. Because ChatGPT can provide human-like responses to complex questions, it could become an easily accessible source of medical advice for patients. However, its ability to answer medical questions appropriately and equitably remains unknown. We presented ChatGPT with 96 advice-seeking vignettes that varied across clinical contexts, medical histories, and social characteristics. We analyzed responses for clinical appropriateness by concordance with guidelines, recommendation type, and consideration of social factors. Ninety-three (97%) responses were appropriate and did not explicitly violate clinical guidelines. Recommendations in response to advice-seeking questions were completely absent (N=34, 35%), general (N=18, 18%), or specific (N=44, 46%). Fifty-three (55%) explicitly considered social factors like race or insurance status, which in some cases changed clinical recommendations. ChatGPT consistently provided background information in response to medical questions but did not reliably offer appropriate and personalized medical advice.

COVID-19 amplified racial disparities in the U.S. criminal legal system
Brennan Klein, C. Brandon Ogbunugafor, Benjamin J. Schafer, Zarana Bhadricha, Preeti Kori, Jim Sheldon, Nitish Kaza, Arush Sharma, Emily A. Wang, Tina Eliassi-Rad, Samuel V. Scarpino, Elizabeth Hinton

Task shifting healthcare services in the post-COVID world: A scoping review
Shukanto Das, Liz Grant

Comparing human and artificial intelligence in writing for health journals: an exploratory study
Zaeem ul Haq, Huzaifa Naeem, Ayesha Naeem, Faisal Iqbal, Durayya Zaeem
medRxiv 2023.02.22.23286322; doi: https://doi.org/10.1101/2023.02.22.23286322

ABSTRACT
Aim and objectives
The aim was to contribute to the editorial principles on the possible use of Artificial Intelligence (AI)-based tools for scientific writing.
The objectives included
A. Enlist the inclusion and exclusion criteria to test ChatGPT use in scientific writing
B. Develop evaluation criteria to assess the quality of articles written by human authors and ChatGPT
C. Compare prospectively written manuscripts by human authors and ChatGPT

Design
Prospective exploratory study

Intervention
Human authors and ChatGPT were asked to write short journal articles on three topics: 1) Promotion of early childhood development in Pakistan 2) Interventions to improve gender-responsive health services in low-and-middle-income countries, and 3) The pitfalls in risk communication for COVID-19. We content analyzed the articles using an evaluation matrix.

Outcome measures
The completeness, credibility, and scientific content of an article. Completeness meant that structure (IMRaD) and organization was maintained. Credibility required that others work is duly cited, with an accurate bibliography. Scientific content required specificity, data accuracy, cohesion, inclusivity, confidentiality, limitations, readability, and time efficiency.

Results
The articles by human authors scored better than ChatGPT in completeness and credibility. Similarly, human-written articles scored better for most of the items in scientific content except for time efficiency where ChatGPT scored better. The methods section was absent in ChatGPT articles, and a majority of references in its bibliography were unverifiable.

Conclusions
ChatGPT generates content that is believable but may not be true. The creators of this powerful model must step up and provide solutions to manage its glitches and potential misuse. In parallel, the academic departments, editors, and publishers must expect a growing utilization of ChatGPT and similar tools. Disallowing ChatGPT as a co-author may not be enough on their part. They must adapt the editorial policies, use measures to detect AI-based writing, and stop its likely implications for human health and life.

STRENGTHS AND LIMITATIONS
- First study that examines the scientific writing of ChatGPT by comparing it with human-written articles.
- Explains how ChatGPT generates believable content that may not be true.
- Indicates that the creators of ChatGPT must step up to address its misuse and potential hazards.
- An initial exploration, based on limited data—larger studies are needed for generalizable conclusions.

Competing Interest Statement
The authors have declared no competing interest.

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 06 Jan 2023]
[Provider Filter: OSF Pre-prints  Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
No new digest content identified; We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value.


**Selected Research**

**Open Letter  Open Access**

**Multimorbidity research in Sub-Saharan Africa: Proceedings of an interdisciplinary workshop** [version 1; peer review: awaiting peer review]
Gift T. Banda, et al. on behalf of the workshop contributors (listed in the acknowledgements)

**Abstract**

As life expectancies rise globally, the number of people living with multiple chronic health conditions—commonly referred to as ‘multimorbidity’—is rising. Multimorbidity has been recognised as especially challenging to respond to in countries whose health systems are under-funded, fragmented, and designed primarily for acute care, including in sub-Saharan Africa. A growing body of research in sub-Saharan Africa has sought to better understand the particular challenges multimorbidity poses in the region and to develop context-sensitive responses. However, with multimorbidity still crystallising as a subject of enquiry, there remains considerable heterogeneity in conceptualising multimorbidity across disciplines and fields, hindering coordinated action. In June 2022, 60 researchers, practitioners, and stakeholders with regional expertise from nine sub-Saharan African countries gathered in Blantyre, Malawi to discuss ongoing multimorbidity research across the region. Drawing on insights from disciplines including epidemiology, public health, clinical medicine, anthropology, history, and sociology, participants critically considered the meaning, singular potential, and limitations of the concept of multimorbidity in sub-Saharan Africa. The workshop emphasised the need to move beyond a disease-centred concept of multimorbidity to one foregrounding patients’ values, needs, and social context; the importance of foregrounding structures and systems rather than behaviour and lifestyles; the value of a flexible (rather than standard) definition of multimorbidity; and the need to leverage local knowledge, expertise, resources, and infrastructure. The workshop further served as a platform for exploring opportunities for training, writing, and ongoing collaboration.

---

**Research Article  Open Access**

**REVISED Perceptions about controlled human infection model (CHIM) studies among members of ethics committees of Indian medical institutions: A qualitative exploration** [version 2; peer review: 1 approved, 1 not approved]
Abhishek Sharma, et al.

**Abstract**

Introduction: Controlled Human Infection Model (CHIM) studies provide a unique platform for studying the pathophysiology of infectious diseases and accelerated testing of vaccines and drugs in controlled settings. However, ethical issues shroud them as the disease-causing pathogen is intentionally inoculated into healthy consenting volunteers, and effective treatment may or may not be available. We explored the perceptions of the members of institutional ethics committees (IECs) in India about CHIM studies.

Methods: This qualitative exploratory study, conducted across seven sites in India, included 11 focused group discussions (FGD) and 31 in-depth interviews (IDI). A flexible approach was used with the aid of a topic guide. The data were thematically analyzed using grounded theory and an inductive approach. Emerging themes and sub-themes were analyzed, and major emergent themes were elucidated.

Results: Seventy-two IEC members participated in the study including 21 basic medical scientists, 29 clinicians, 9 lay people, 6 legal experts and 7 social scientists. Three major themes emerged from this analysis—apprehensions about conduct of CHIM studies in India, a perceived need for CHIM studies in India and risk mitigation measures needed to protect research participants and minimize the associated
risks. 
Conclusion: Development of a specific regulatory and ethical framework, training of research staff and ethics committee members, and ensuring specialized research infrastructure along with adequate community sensitization were considered essential before initiation of CHIM studies in India.

* *** * *

Think Tanks

**Brookings**  [to04 Mar 2023]
http://www.brookings.edu/
Latest Research [Selected] Technology & Innovation
All Research [Selected] CGD NOTES
No new digest content identified.

**Center for Global Development**  [to 04 Mar 2023]
https://www.cgdev.org/
All Research [Selected]
WORKING PAPERS
**Competition and Firm Recovery Post-COVID-19**
Miriam Bruhn et al.
March 03, 2023
This paper examines the impact of the COVID-19 crisis on the reallocation of economic activity across firms, and whether this reallocation depends on the competition environment. The paper uses the World Bank’s Enterprise Surveys COVID-19 Follow-up Surveys for about 8,000 firms, including both small...

**CGD NOTES**
**The Next Pandemic: If We Can’t Respond, We’re Not Prepared**
Cristina Stefan et al.
February 28, 2023
The policy discussions about PPR are noteworthy. But the global public sector is underinvesting in pandemic response. This creates the illusion of safety without the finance or planning in place to provide it. We cannot delay planning for response financing when the next pandemic hits, by which time...

**POLICY PAPERS**
**Reimagining Global Health Financing: How Refocusing Health Aid at the Margin Could Strengthen Health Systems and Futureproof Aid Financial Flows**
Tom Drake et al.
February 27, 2023
Health aid has helped domestic financing achieve historic gains in global health but there is much still to be done. Six major issues prevent aid from being more effective, fit for the future, and aligned with country priorities: funding volatility, aid fragmentation, the displacement of domestic fi...
Chatham House  [to 04 Mar 2023]
https://www.chathamhouse.org/
Selected Analysis, Comment, Events
No new digest content identified.

CSIS  [to04 Mar 2023]
https://www.csis.org/
Selected Reports, Events
No new digest content identified.

Kaiser Family Foundation  [to04 Mar 2023]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

McKinsey Global Institute
https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

ODI  [Overseas Development Institute]  [to 04 Mar 2023]
Publications [Selected]
Financing social assistance in lower-income countries post-Covid-19: An exploration of realistic options
03 March 2023
Working papers

Pew Research Center  [to 04 Mar 2023]
https://www.pewresearch.org/
Latest Publications [Selected]
No new digest content identified.

Rand  [to 04 Mar 2023]
https://www.rand.org/pubs.html
Published Research [Selected]
Report
Quantifying the link between COVID-19, conflict risk, and the global economy
Our research suggests that COVID-19 will significantly increase the risk of civil conflict in African countries. We estimate this effect will, in turn, have negative global repercussions via international trade losses.
Mar 3, 2023
Grant Johnson, Sean M. Zeigler, Marco Hafner, Catherine Galley

*Journal Article*

**A New Ethical Principle for Analysts Who Use Models**

Analysts have long embraced the ethic of revealing assumptions that underlie their conclusions. Analysts should preemptively explain how their conclusions vary with changes of important assumptions reflecting uncertainties and disagreements.

Mar 3, 2023
Paul K. Davis

*Urban Institute*  [to 04 Mar 2023]
https://www.urban.org/publications

*New Research Publications - Selected*

*World Economic Forum*  [to 04 Mar 2023]
https://agenda.weforum.org/news/

*Media*

No new digest content identified.

--------

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

--------

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

--------

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable
development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*       *       *       *
*       *       *       *